Form 4: Voyager Therapeutics COO Sells Shares for Tax Obligations

Voyager Therapeutics' COO and CBO, Robin Swartz, reported a non-discretionary sale of 6,458 common shares to cover tax withholding obligations related to RSU vesting.

Summary

• Robin Swartz, the Chief Operating Officer and Chief Business Officer of Voyager Therapeutics, Inc. (VYGR), reported a transaction involving the company's common stock.
• The transaction, which occurred on February 24, 2026, was a sale of 6,458 shares of common stock.
• The shares were sold at a weighted average price of $3.77 per share, with individual transaction prices ranging from $3.61 to $3.86.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) on February 21, 2026.
• This sale was executed pursuant to a durable automatic sale instruction (a Rule 10b5-1 plan) adopted by Robin Swartz on May 12, 2025, and does not represent a discretionary trade.
• Following this transaction, Robin Swartz beneficially owns 199,738 shares of Voyager Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a pre-planned, non-discretionary transaction to cover tax obligations associated with RSU vesting, rather than a discretionary decision to reduce exposure to the company's stock.

Negatives

• The sale of shares by an insider, even for tax purposes, can sometimes be misinterpreted by less informed investors as a lack of confidence in the company.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports a past insider transaction.

Industry Context

StockSavvy.ai notes that routine 'sell-to-cover' transactions under Rule 10b5-1 plans are common among executives in the biotechnology sector and generally do not signal a change in management's confidence in the company's long-term prospects. These sales are a standard mechanism for executives to manage tax liabilities arising from equity compensation.

Comparison to Industry Standards

• StockSavvy.ai observes that such tax-related sales are standard practice across industries, including biotech, for executives receiving equity compensation.
• For instance, similar transactions are frequently seen at companies like Biogen or Moderna when RSUs vest, where executives sell a portion of shares to cover statutory tax obligations, rather than indicating a bearish outlook.

Stakeholder Impact

• Shareholders: The sale of shares, even for tax purposes, slightly increases the float and could be perceived negatively by uninformed investors, though sophisticated investors understand it as a routine event and not a signal of lack of confidence.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale by an insider to cover tax obligations associated with restricted stock unit vesting. It does not reflect a change in the insider's discretionary investment decision or a signal about the company's future performance, thus maintaining a 'hold' recommendation based solely on this filing.

Keywords

Voyager Therapeutics, VYGR, Robin Swartz, Insider Trading, Form 4, Stock Sale, Tax Withholding, RSU Vesting, Rule 10b5-1, Biotechnology